Three female researchers wearing lab coats looking at and pointing to information on a computer screen

EMBRACE: A study to collect information about people who have inherited faulty cancer genes

Trial at a glance

Open trial

  • Cancer type: Prevention/BRCA
  • Treatment stage: Prevention or diagnosis
  • Acronym: EMBRACE

Epidemiological Study of Familial Breast Cancer

Who can take part

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.


You may be eligible to take part if you:

  • ​have been identified through your GP as being at high risk of having a genetic mutation and have been referred to a clinical genetics service for counselling
  • are a member of a family known to have a genetic mutation and have been referred to a clinical genetics service for counselling
  • have had or will have testing for genetic mutations 
  • have declined a predictive gene test but have been counselled by a genetics clinic

This is not an exhaustive list. Anyone who is interested in participating in a clinical trial should speak to their own doctor about what other criteria might apply.

This study is interested in the following genes:

  • BRCA1
  • BRCA2
  • PALB2
  • ATM
  • CHEK2
  • BRIP1
  • RAD51C
  • RAD51D
  • BARD1
  • PTEN
  • TP53
  • CDH1

About the trial

This study collects information about people who have inherited faulty cancer genes. Inheriting a faulty gene means that a person is at a higher risk of developing certain cancers.

A fault in the BRCA1 or BRCA2 genes means that a person is more likely to develop cancers of the breast, ovary or prostate. As well as the BRCA1 and BRCA2 genes, we now know that other genes are associated with breast and/or ovarian cancer risk. The risk from these other genes is generally much lower and not as well understood as BRCA1 and BRCA2. 

The study looks to develop a register of BRCA1 and BRCA2 families. It also wants to create a register of families who have a fault in the other genes. This helps to find out more about their associated cancer type and risk.

People taking part in the study will be asked to:

  • fill in a questionnaire
  • give blood samples which will be looked at in a laboratory

Some of the recruits will be followed up with further questionnaires and for blood samples.

With this information researchers hope to find out:

  • how many people go on to develop cancer
  • what other factors may play a part in the development of cancer including lifestyle factors, the individuals’ genetic make up
  • how the cancer risk may be reduced
  • how changes or markers in the blood could be used to be able to detect early cancer

The findings of this study will continue to collate information that will help doctors to decide the best way to care for someone who has these faulty genes.

Clinical trial locations